The growing field of immunotherapy relies heavily on recombinant mediator technology, and a precise understanding of individual profiles is essential for refining experimental design and therapeutic efficacy. Specifically, examining the characteristics of recombinant IL-1A, IL-1B, IL-2, and IL-3 reveals notable differences in their molecular makeup